Literature DB >> 26091736

Why We Should Be Willing to Pay for Hepatitis C Treatment.

Jagpreet Chhatwal1, Qiushi Chen2, Fasiha Kanwal3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26091736      PMCID： PMC4575858          DOI： 10.1016/j.cgh.2015.06.005

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  17 in total

Review 1.  The lifetime cost of current human immunodeficiency virus care in the United States.

Authors:  Bruce R Schackman; Kelly A Gebo; Rochelle P Walensky; Elena Losina; Tammy Muccio; Paul E Sax; Milton C Weinstein; George R Seage; Richard D Moore; Kenneth A Freedberg
Journal:  Med Care       Date:  2006-11       Impact factor: 2.983

2.  The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.

Authors:  David B Rein; John S Wittenborn; Bryce D Smith; Danielle K Liffmann; John W Ward
Journal:  Clin Infect Dis       Date:  2015-03-16       Impact factor: 9.079

3.  Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.

Authors:  Mehdi Najafzadeh; Karin Andersson; William H Shrank; Alexis A Krumme; Olga S Matlin; Troyen Brennan; Jerry Avorn; Niteesh K Choudhry
Journal:  Ann Intern Med       Date:  2015-03-17       Impact factor: 25.391

4.  The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

Authors:  Kathleen N Ly; Jian Xing; R Monina Klevens; Ruth B Jiles; John W Ward; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2012-02-21       Impact factor: 25.391

5.  New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.

Authors:  Shan Liu; Lauren E Cipriano; Mark Holodniy; Douglas K Owens; Jeremy D Goldhaber-Fiebert
Journal:  Ann Intern Med       Date:  2012-02-21       Impact factor: 25.391

6.  Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.

Authors:  Hiroyo Kuwabara; Kirsten Westerhout; Maarten Treur; Karin Cerri; Joerg Mahlich; Hiroshi Yatsuhashi
Journal:  J Med Econ       Date:  2015-03-31       Impact factor: 2.448

7.  The changing burden of hepatitis C virus infection in the United States: model-based predictions.

Authors:  Mina Kabiri; Alison B Jazwinski; Mark S Roberts; Andrew J Schaefer; Jagpreet Chhatwal
Journal:  Ann Intern Med       Date:  2014-08-05       Impact factor: 25.391

Review 8.  Cost-effectiveness of HIV testing and treatment in the United States.

Authors:  Rochelle P Walensky; Kenneth A Freedberg; Milton C Weinstein; A David Paltiel
Journal:  Clin Infect Dis       Date:  2007-12-15       Impact factor: 9.079

9.  The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

Authors:  Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim
Journal:  Ann Intern Med       Date:  2015-05-05       Impact factor: 51.598

10.  Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C.

Authors:  Anita J Brogan; Sandra E Talbird; James R Thompson; Jeffrey D Miller; Jaime Rubin; Baris Deniz
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240
View more
  4 in total

1.  Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents.

Authors:  A M Moon; P K Green; K Berry; G N Ioannou
Journal:  Aliment Pharmacol Ther       Date:  2017-03-08       Impact factor: 8.171

Review 2.  Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease.

Authors:  Lorenzo Leggio; Mary R Lee
Journal:  Am J Med       Date:  2016-10-29       Impact factor: 4.965

3.  Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals.

Authors:  Mark S Roberts; Fasiha Kanwal; Jagpreet Chhatwal; Xiaojie Wang; Turgay Ayer; Mina Kabiri; Raymond T Chung; Chin Hur; Julie M Donohue
Journal:  Hepatology       Date:  2016-06-01       Impact factor: 17.425

4.  Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy.

Authors:  Nadia A Nabulsi; Michelle T Martin; Lisa K Sharp; David E Koren; Robyn Teply; Autumn Zuckerman; Todd A Lee
Journal:  Front Pharmacol       Date:  2020-11-13       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.